COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,252 Articles (22,733 medRxiv, 8,519 bioRxiv)

Most recent first Previous |  Page 495: Articles 4941-4950  | Next

Underlying driving forces of the SARS-CoV-2 evolution: immune evasion and ACE2 binding affinity
Ma, W., Fu, H., Jian, F., Cao, Y., Li, M.
10.1101/2023.02.06.527236 — Posted: 2023-02-07
A COVID-19 DNA Vaccine Candidate Elicits Broadly Neutralizing Antibodies Against Multiple SARS-CoV-2 Variants Including the Currently Circulating Omicron BF.5, BF.7, BQ.1 and XBB
Ding, Y., Fan, F., Xu, X., Zhao, G., Zhang, X., Zhao, H., Wang, L., Wang, B., Gao, X.-M.
10.1101/2023.02.06.527382 — Posted: 2023-02-07
Elevated binding and functional antibody responses to SARS-CoV-2 in infants versus mothers
Stoddard, C. I., Sung, K., Yaffe, Z. A., Weight, H., Beaudoin-Bussieres, G., Galloway, J. G., Gantt, S., Adhiambo, J., Begnel, E. R., Ojee, E., Slyker, J., Wamalwa, D., Kinuthia, J., Finzi, A., Matsen, F. A., Lehman, D. A., Overbaugh, J.
10.1101/2023.02.06.527330 — Posted: 2023-02-07
A SARS-CoV-2 vaccine designed for manufacturability results in unexpected potency and non-waning humoral response
Campbell, E., Dobkin, J., Osorio, L., Ramasamy, S., Kumar, R., SantAngelo, D. B., Subbian, S., Denzin, L. K., Anderson, S.
10.1101/2023.02.06.527376 — Posted: 2023-02-07
Heterologous inactivated virus/mRNA vaccination response to BF.7, BQ.1.1, and XBB.1
Zuo, F., Sun, R., Abolhassani, H., Du, L., Wang, Y., Vlachiotis, S., Bertoglio, F., Schubert, M., Rezaei, N., Chavoshzadeh, Z., Guerra, C., Cavalli, A., Andrell, J., Kumagai-Braesch, M., Xue, Y., Cao, Y., Hust, M., F. Robbiani, D., Xie, X., Hammarstrom, L., Marcotte, H., Pan-Hammarstrom, Q.
10.1101/2023.02.02.23285205 — Posted: 2023-02-07
Associations of COVID-19 Symptoms with Omicron Subvariants BA.2 and BA.5, Host Status, and Clinical Outcomes: A Registry-Based Observational Study in Sapporo, Japan
Nakakubo, S., Kishida, N., Okuda, K., Kamada, K., Iwama, M., Suzuki, M., Yokota, I., Ito, Y. M., Nasuhara, Y., Boucher, R. C., Konno, S.
10.1101/2023.02.02.23285393 — Posted: 2023-02-07
Longitudinal and Quantitative Fecal Shedding Dynamics of SARS-CoV-2, Pepper Mild Mottle Virus and CrAssphage
Arts, P. J., Kelly, J. D., Midgley, C. M., Anglin, K., Lu, S., Abedi, G. R., Andino, R. N., Bakker, K. M., Banman, B., Boehm, A., Briggs-Hagen, M., Brouwer, A. F., Davidson, M. C., Eisenberg, M. C., Garcia Knight, M. A., Knight, S., Peluso, M. J., Pineda-Ramirez, J., Tassetto, M., Diaz-Sanchez, R., Saydeh, S., Martin, J. N., Wigginton, K. R.
10.1101/2023.02.02.23285391 — Posted: 2023-02-07
Safety, Virology, Pharmacokinetics, and Clinical Experience of High-dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-label Clinical Trial
Moya, J., Temech, M., Parra, S., Juarez, E., Hernandez-Loy, R., Moises Gutierrez, J. C., Diaz, J., Hussain, R., Segal, S., Xu, C., Skingsley, A., Schnell, G., El-Zailik, A., Sager, J. E., Aldinger, M., Alexander, E. L., Acloque, G.
10.1101/2023.02.02.23285352 — Posted: 2023-02-07
Bioinformatic analysis of the spike protein cleavage sites of coronaviruses in the mammalian order Eulipotyphla
Guo, Q., Choi, A., Millet, J., Whittaker, G.
10.1101/2023.02.05.527216 — Posted: 2023-02-06
Prior vaccination enhances immune responses during SARS-CoV-2 breakthrough infection with early activation of memory T cells followed by production of potent neutralizing antibodies
Painter, M. M., Johnston, T. S., Lundgreen, K. A., Santos, J. J. S., Qin, J. S., Goel, R. R., Apostolidis, S. A., Mathew, D., Fulmer, B., Williams, J. C., McKeague, M. L., Pattekar, A., Goode, A., Nasta, S., Baxter, A. E., Giles, J. R., Skelly, A. N., Felley, L. E., McLaughlin, M., Weaver, J., Penn Medicine BioBank, , Kuthuru, O., Dougherty, J., Adamski, S., Long, S., Kee, M., Clendenin, C., da Silva Antunes, R., Grifoni, A., Weiskopf, D., Sette, A., Huang, A. C., Rader, D. J., Hensley, S. E., Bates, P., Greenplate, A. R., Wherry, E. J.
10.1101/2023.02.05.527215 — Posted: 2023-02-06

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).